GenomeWeb, the leading news source for the molecular diagnostics industry, has profiled Sparrow Bio and our $100 personal DNA analyzer.
Companies have spent billions trying to make PCR affordable. In the article, CEO Paul Lem, M.D., explains how the economics finally work for at-home PCR.
“At the end of the day, you have to create a product that is actually profitable to sell and that is also affordable to consumers,” he said.
Sparrow is now seeking partners to fund test menu development and regulatory clearances.
Read the full article: GenomeWeb link
Sparrow's vision is better healthcare for billions of people—with a personal DNA analyzer in every home. This will enable rapid diagnosis of Sexually Transmitted Diseases, Respiratory infections, Cancer, Food and Water pathogens, Genetic risks, and many other applications. This is the future of medicine. It is now possible because Sparrow has invented technologies that reduce PCR manufacturing costs by up to 50X, thus enabling a new billion-dollar market for consumer testing at home.
